

Protocol Pha	se: □ Phase I □ Phase II □ Phase IV □ Device
Sponsor/CRO Protocol Art	O:icle:
Drug Administration: □ N/A □ PO □ SQ □ IM □IV Other Critical Descriptor:	
POPULAT	
1. What is the	e population age?
3. What type	e participant health status? life threatening chronic healthy of treatment population is required? number of participants expected to enroll?
3. What type 64. What is the	of treatment population is required?
3. What type 64. What is the5. Is the number	of treatment population is required?e number of participants expected to enroll?
3. What type 64. What is the5. Is the numb6. Do we have	of treatment population is required?
3. What type of 4. What is the5. Is the number of 5. Do we have7. Are the inc	of treatment population is required?
 3. What type of 4. What is the 4. What is the 5. Is the number of 6. Do we have 7. Are the inc * Seasonal if * Concerns 	of treatment population is required?
 3. What type of the state of the st	of treatment population is required?
 3. What type of the state of the st	of treatment population is required?



PROTOCOL		
1. Is the protocol	complex with multiple arms? □Yes □ No	
2. Is the protocol	ethical? □Yes □ No	
3. Do you forese	e the IRB having problems with the protocol? □Yes □ No	
4. Do you forese	e any participant compliance issues? □Yes □ No	
5. Will coordinat	ion with other departments/services be required? □Yes □ No	
6. What departm	ents/services? ☐ Lab ☐ Radiology ☐ Pharmacy ☐ Pathology	
□ CCTS: □ CF	RU □ CRSP □ Bionutrition □ Biospecimen □ Other	
7. Clinical Billab	oles? □Yes □ No	
8. Duration of stu	udy? □Yes □ No	
9. Inpatient, outp	eatient or both? □Inpatient □ Outpatient □Both	
10 D (1 ' ')	seem complex and time consuming? □Yes □ No	
10. Do the visits	6 T	
	schedule complex? □Yes □ No	
11. Is the dosing	schedule complex? □Yes □ No	
11. Is the dosing		
11. Is the dosing	schedule complex? □Yes □ No	
11. Is the dosing	schedule complex? □Yes □ No	
11. Is the dosing	schedule complex? □Yes □ No	
11. Is the dosing Comments:	schedule complex? □Yes □ No	
11. Is the dosing Comments: PRO	schedule complex? □Yes □ No	
11. Is the dosing Comments: PRO	schedule complex? □Yes □ No OCEDURES	
PRO 1 2	schedule complex? □Yes □ No OCEDURES Are the procedures/clinical assessments complex? □Yes □ No	
PRO 1 2	schedule complex? □Yes □ No OCEDURES Are the procedures/clinical assessments complex? □Yes □ No Is there a washout period? □Yes □ No	
PRO 1 2 3	schedule complex? □Yes □ No OCEDURES Are the procedures/clinical assessments complex? □Yes □ No Is there a washout period? □Yes □ No	
PRO 1 2 3	schedule complex? □Yes □ No OCEDURES Are the procedures/clinical assessments complex? □Yes □ No Is there a washout period? □Yes □ No What procedures will be performed?	



STAFF

1. Is the workload manageable? \square Yes \square No
2. Is additional training necessary? □Yes □ No
3. What training? □Start up, □diaries, □electronic devices? □Investigator meeting?
□Other
4. Adequate staff to conduct the study? □Yes □ No
5. Will the study require extended work hours, on call time, weekends? □Yes □ No
6. Additional specialists/consults needed? □Yes □ No
7. Will budget cover expenses? □Yes □ No
Time Estimates (How many hours of your time do you estimate for the items below?)
1. Recruitment? *Please also complete Recruitment and Retention
Form
3. Monitor visits?4. Addressing queries?
5. Entering data?
6. Source docs?
7. EDC?
8. Scheduling visits & procedures?
9. Will it be convenient or will pts miss work and school?
10. Managing adverse events?
Comments about time requirements?
Experience with Sponsor/CRO? Yes No
Comments about
sponsor/CRO



RECOMMENDATION:
Pursue protocol □Yes □ No
Pursue with conditions (explain below) □Yes □ No
Do not pursue (explain below) □Yes □ No
Comments:
COMPLETED BY:
PI SIGNATURE:
DATE: